Pegylated interferon alpha (PEG-IFN-α) is widely used to treat chronic hepatitis C in combination with ribavirin. Many adverse effects of PEG-IFN-α, such as hematologic, psychologic, dermatologic, immunologic, and other abnormalities, have been reported, and some serious adverse events lead to PEG-IFN-α treatment discontinuation. For very rare adverse events such as panniculitis, there are no established guidelines on whether to continue PEG-IFN-α treatment. Published reports on panniculitis induced by PEG-IFN-α 2a are sparse. Herein we report a case of repeated occurrences of panniculitis in a patient with chronic hepatitis C, leading to treatment cessation.

Download full-text PDF

Source
http://dx.doi.org/10.4166/kjg.2016.67.5.272DOI Listing

Publication Analysis

Top Keywords

chronic hepatitis
12
panniculitis induced
8
pegylated interferon
8
interferon alpha
8
patient chronic
8
adverse events
8
peg-ifn-α treatment
8
peg-ifn-α
5
repeated panniculitis
4
induced pegylated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!